Ahmad Tarhini, MD
Hematology & Oncology · Pittsburgh, PANPI 1811934755
Payments from drug & device makers
Across 821 payments — averaging $9022.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$2.5M
- Regeneron$1.4M
- Pfizer$691K
- Genentech, Inc.$569K
- E.r. Squibb & Sons, L.L.C.$461K
- Novartis$436K
- plus $1.4M from 19 others
Across 12 payments — averaging $4652.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$26K
- Novartis$22K
- Teva Pharmaceuticals USA, Inc.$7K
- F. Hoffmann-la Roche AG$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 69 | $2,479,536 |
| Regeneron | 389 | $1,416,732 |
| Pfizer | 8 | $690,786 |
| Genentech, Inc. | 108 | $568,841 |
| E.r. Squibb & Sons, L.L.C. | 28 | $460,923 |
| Novartis | 21 | $435,697 |
| Sanofi US Services Inc. | 44 | $407,509 |
| Hoffmann-la Roche Limited | 40 | $346,700 |
| Roche Products Limited | 31 | $337,161 |
| Clinigen, Inc. | 5 | $139,990 |
| Iovance Biotherapeutics, Inc. | 1 | $28,095 |
| Acrotech Biopharma Inc. | 9 | $23,850 |
| Partner Therapeutics, Inc. | 5 | $18,302 |
| F. Hoffmann-la Roche AG | 4 | $16,073 |
| Sanofi | 3 | $12,777 |
| Eisai Inc. | 3 | $5,000 |
| Genentech USA, Inc. | 3 | $4,505 |
| Regeneron Healthcare Solutions, Inc. | 1 | $3,275 |
| Amgen | 1 | $3,218 |
| AstraZeneca | 1 | $2,740 |
| Array Biopharma Inc | 5 | $2,538 |
| Incyte Corporation | 39 | $1,661 |
| Bayer | 1 | $1,000 |
| Modernatx, Inc. | 1 | $650 |
| Sun Pharmaceutical Industries Inc. | 1 | $146 |
How this compares
$7,407,702 in reported general payments places this provider in the 95th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Pittsburgh
- Diwakar DavarPittsburgh$21.6M
- Jason LukePittsburgh$15M
- Leonard ApplemanPittsburgh$12.8M
- Jing Zhou HouPittsburgh$11.9M
- Taofeek OwonikokoPittsburgh$9.7M
- Samuel JacobsPittsburgh$6.5M
- Cyrus KhanPittsburgh$4.5M
- Kathleen DorritiePittsburgh$3.2M
- Salman FazalPittsburgh$2.9M
- Mounzer AghaPittsburgh$2.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.